Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNAH5 antisense RNA 1 (DNAH5-AS1) is an antisense non-coding RNA transcript that is transcribed from the DNAH5 gene locus. As a long non-coding RNA, DNAH5-AS1 is presumed to regulate expression of the DNAH5 gene or its genomic neighborhood by mechanisms common to antisense RNAs—such as modulating gene transcription, affecting mRNA stability or translation, and participating in locus-specific epigenetic regulation[2][4]. Antisense RNAs are increasingly recognized as important regulators in a wide variety of biological and pathophysiological processes, including X-chromosome inactivation and cancer[2]. However, there is currently no evidence that DNAH5-AS1 itself is a classical therapeutic target (such as a receptor or enzyme), or that drugs directly target this RNA. It is also not yet directly linked as a biomarker or direct contributor to diseases associated with DNAH5 (such as primary ciliary dyskinesia), though dysregulation of antisense RNAs is a mechanism observed in various disorders[2][4].
Not applicable (not a direct drug target or enzyme/receptor); general mechanisms of antisense lncRNAs include gene silencing, epigenetic regulation, and mRNA modulation[2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNAH5 antisense RNA 1 (DNAH5-AS1).